allergan

Allergan bolsters skincare portfolio with Elastagen acquisition for $95 million

pharmafile | February 7, 2018 | News story | Research and Development, Sales and Marketing |  Allergan, Elastagen, M&A, MA, pharma 

Pharma’s M&A train keeps on going as news breaks that Allergan has picked up University of Sydney spin-off Elastagen for $95 million. The deal means that multi-national biopharma firm acquires Elastagen’s tropoelastin, which is used to treat acne scars and stretch marks, to complement its own skincare portfolio, which includes the famous product Botox.

Elastagen’s product is based on tropoelastin found in the human body, which is a precursor to the highly elastic protein elastin and allows tissues to maintain their shape, resulting in youthful-looking skin.

“Our technology has come a long way from the lab bench at the University of Sydney towards developing products for patients around the world,” commented Professor Anthony Weiss, Elastagen’s founding scientist. “I thank my team at the University of Sydney and greatly look forward to seeing our science commercialized by Allergan.”

Advertisement

In 2016, Elastagen closed a £13 million Series B financing round, attracting investors including the Wellcome Trust, AMOREPACIFIC Ventures and Korea Investment Partners, while existing investors Brandon Capital Partners, ATP Innovations and GBS Ventures also participated. The company was also one of the inaugural recipients of the NSW State Government Medical Devices Fund in 2013.

Bill Meury, Chief Commercial Officer at Allergan, said of the deal: “This acquisition and the development of a next generation of injectables based on this technology will ensure Allergan offers innovative filler products for years to come.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content